Brii BiosciencesFRA:7SS -2.05%33 Quick Ratio is 60.74 as of Dec. 2025, which is 324% above its 10-year median of 14.31. GuruFocus rates FRA:7SS with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, Brii Biosciences ranks better than 99.15% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Brii Biosciences's quick ratio for the quarter that ended in Dec. 2025 was 60.74.
Brii Biosciences has a quick ratio of 60.74. It generally indicates good short-term financial strength.
The historical rank and industry rank for Brii Biosciences's Quick Ratio or its related term are showing as below:
FRA:7SS'
s Quick Ratio Range Over the Past 10 Years
Min: 1.9 Med: 14.31 Max: 60.73
Current: 60.73
During the past 7 years, Brii Biosciences's highest Quick Ratio was 60.73. The lowest was 1.90. And the median was 14.31.
FRA:7SS's Quick Ratio is ranked better than 99.15% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs FRA:7SS: 60.73
Brii Biosciences (FRA:7SS) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Brii Biosciences Quick Ratio Related Terms
Brii Biosciences Quick Ratio Historical Data
* Premium members only.
The historical data trend for Brii Biosciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7SS vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Brii Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brii Biosciences Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brii Biosciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Brii Biosciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Brii Biosciences's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brii Biosciences (FRA:7SS) has a Quick Ratio of 60.74 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Brii Biosciences and its competitors. This is 324% above median its historical median of 14.31. Over the past decade, Brii Biosciences' Quick Ratio has ranged from 1.90 to 60.73. According to the industry distribution chart, Brii Biosciences ranks #12 out of 1416 companies in the Biotechnology industry, placing it in the top 0.8%.
Is Brii Biosciences' Quick Ratio too high?
Brii Biosciences' current Quick Ratio of 60.74 is 324% above median its 10-year median of 14.31. Over the past 10 years, this metric has ranged from a low of 1.90 to a high of 60.73. The Biotechnology industry median Quick Ratio is 3.60. Brii Biosciences' value of 60.74 is 1587.2% above this industry median. Based on the distribution chart, Brii Biosciences ranks #12 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Brii Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Brii Biosciences' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brii Biosciences ranks #12 out of 1416 companies for Quick Ratio. This places Brii Biosciences in the top 1% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Brii Biosciences' value of 60.74 is 1587.2% above this benchmark. Historically, Brii Biosciences' own Quick Ratio has ranged from 1.90 to 60.73 over the past decade. While the company's 10-year median is 14.31 vs. the industry median of 3.60, Brii Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brii Biosciences's current Quick Ratio of 60.74 is 1587.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Brii Biosciences and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brii Biosciences's current Quick Ratio is 60.74, which is 324% above median its own 10-year median of 14.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brii Biosciences stock overvalued right now?
Brii Biosciences (FRA:7SS) has a current Quick Ratio of 60.74. The current Quick Ratio is 60.74, which is 324% above median its 10-year median of 14.31 and 1587.2% above the Biotechnology industry median of 3.60. Brii Biosciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Brii Biosciences (FRA:7SS), the current Quick Ratio is 60.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AddressNo. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
33GF Score
Get the complete analysis for FRA:7SS
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7SS has been successfully added to your 
